Angiogenesis: An update and potential drug approaches (Review)

Maen Abdelrahim, Santhi Konduri, Riyaz Mahammad Basha, Philip A. Philip, Cheryl H. Baker

Research output: Contribution to journalReview article

41 Scopus citations

Abstract

The therapeutic potential of targeting tumor endothelium and vascular supply is now widely recognized to treat different diseases. One such disease is cancer; where endothelial cells are actively proliferating to support the tumor growth. Solid tumors cannot grow beyond the size of a few millimeters without inducing the proliferation of endothelium and formation of new blood vessels. Hence it is crucial to search for new agents that selectively block tumor blood supply. These include anti-angiogenic molecules, vascular disrupting agents or endothelial disrupting agents. The antiangiogenic molecules such as monoclonal antibodies and tyrosine kinase inhibitors disrupt endothelial cell survival mechanisms and new blood vessel formation, and vascular disrupting agents for instance ligand-directed and small molecules can be used to disrupt the already existing abnormal vasculature that support tumors by targeting their dysmorphic endothelial cells. The recent advances in this area of research have identified a variety of investigational agents which are currently in clinical development at various stages and some of these candidates are already approved in cancer treatment. This report will review some of the recent developments and most significant advances in this field and outline future challenges and directions.

Original languageEnglish
Pages (from-to)5-18
Number of pages14
JournalInternational Journal of Oncology
Volume36
Issue number1
DOIs
StatePublished - 1 Jan 2010

    Fingerprint

Keywords

  • Anti-angiogenesis
  • Cancer therapy
  • Tumor endothelium
  • Vascular disrupting agents

Cite this